News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Reported revenue above expectations driven by AI server demand.
  • Market is focused on shrinking gross margins despite revenue beat.
  • Company is deliberately sacrificing margin to secure AI market share.
  • Trade plan: enter $33.00, stop $28.00, target $45.00 over about 45 trading days.
  • Results signal continued strong demand for AI infrastructure.

Latest Articles

Buy EXEL Ahead of a Potential FDA Win — Risk-Weighted Mid-Term Trade

Buy EXEL Ahead of a Potential FDA Win — Risk-Weighted Mid-Term Trade

Exelixis (EXEL) is a profitable oncology company trading near $42.67 with solid free cash flow, low leverage and a pipeline catalyst in zanzalintinib. A favorable FDA outcome could push the stock toward the mid-$40s to $50s; the trade below balances upside with a clear stop and a mid-term time horizon tied to a likely near-term regulatory event.

Tesla to More Than Double Capital Expenditure to Over $20 Billion, Shifting Investment Toward Robots and Autonomous Vehicles

Tesla to More Than Double Capital Expenditure to Over $20 Billion, Shifting Investment Toward Robots and Autonomous Vehicles

Tesla announced plans to boost capital spending to a record exceeding $20 billion this year, more than doubling last year’s outlay, and directing the bulk of that investment away from its traditional human-driven car lineup toward unproven products including fully autonomous vehicles and humanoid robots. Executives said funds will primarily support…

QuantumScape: From Options Trade to Manufacturing Blueprint

QuantumScape: From Options Trade to Manufacturing Blueprint

QuantumScape has moved beyond lab headlines into real vehicle testing and pilot production. With a market cap near $6.0B and a string of OEM and materials partnerships, the risk/reward favors a disciplined long position that targets bet-the-technology upside while protecting capital against execution failure.

Philippine Economy Slows in Q4 as Growth Hits 3%, Below Poll Forecast

Philippine Economy Slows in Q4 as Growth Hits 3%, Below Poll Forecast

The Philippine economy expanded 3% year-on-year in the fourth quarter of 2025, underperforming a median 4% forecast and slowing from a downwardly revised 3.9% growth in the prior quarter. Full-year GDP rose 4.4%, missing the government’s 5.5% to 6.5% target. A corruption scandal that curbed public infrastructure spending last year contributed to th…

Dollar Volatility Persists as Policy Signals and Geopolitics Cloud Outlook

Dollar Volatility Persists as Policy Signals and Geopolitics Cloud Outlook

The U.S. dollar remained under pressure as market participants digested mixed signals from monetary authorities, Washington and European officials after a steep selloff earlier in the week. Investors interpreted a more sanguine Federal Reserve commentary on labor and inflation risks as suggesting interest rates may stay on hold, while supportive re…

Starmer Meets Xi in Beijing as London Seeks a Reset in Bilateral Relations

Starmer Meets Xi in Beijing as London Seeks a Reset in Bilateral Relations

British Prime Minister Keir Starmer will hold a 40-minute meeting with Chinese President Xi Jinping in the Great Hall of the People, followed by lunch, as part of a four-day visit focused on revitalising economic links. Starmer will also meet Premier Li Qiang and top legislator Zhao Leji, and is accompanied by a delegation of more than 50 business …

Minor Insider Sale: National Services Disposes of 10,424 Usio Shares

Minor Insider Sale: National Services Disposes of 10,424 Usio Shares

National Services, Inc., a holder of roughly 10% of Usio, Inc. (NASDAQ: USIO), sold a total of 10,424 common shares on January 26-27, 2026, for about $14,103. The transactions left the shareholder with 2,749,616 shares after the second sale. Usio has reported steady third-quarter 2025 revenue, a decline in adjusted EBITDA, an increased cash balance…

Acumen Pharmaceuticals CLO Sells Shares After Exercising Options; Company Progresses with Alzheimer’s Trials

Acumen Pharmaceuticals CLO Sells Shares After Exercising Options; Company Progresses with Alzheimer’s Trials

Acumen Pharmaceuticals' Chief Legal Officer and Corporate Secretary, Derek M. Meisner, exercised options and then sold the resulting shares under a pre-set 10b5-1 plan on January 26 and January 28, 2026. The transactions involved 17,756 shares and generated proceeds of $53,279. Separately, Acumen reported a net loss for Q3 2025 and continued clinic…